Where MedTech professionals gain clarity and confidence to navigate complex decisions.

Let's Talk Risk! Podcast

Let’s Talk Risk! brings together MedTech leaders and practitioners for thoughtful conversations on the challenges that shape risk, quality, innovation, and leadership. With 150+ episodes and more than 30K downloads, it helps professionals gain the clarity and confidence to lead through complex decisions. naveenagarwalphd.substack.com

Be sure to visit the podcast's website and support the creator: naveenagarwalphd.substack.com

Author

Where MedTech professionals gain clarity and confidence to navigate complex decisions.

Category

Education

Latest episode

Nov 12, 2026

Where to listen?

Podcasts in the app Replaio Radio Coming soon

Podcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts

Get it on Google Play Install for free Android 10M+ downloads · 4.7+ rating iOS soon

Episodes

LTR 82: Tips for Regulatory Success with AI Devices in Radiology 06.03.2025

Summary “Clinicians need to to trust the (AI) algorithm, and knowing how it works helps them understand where it might fail, or where extra attention might be needed.” In this episode of the Let's Talk Risk Podcast , Dr. Jay Vaishnav discusses the rapid growth of artificial intelligence (AI) in the medical technology (MedTech) field, particularly in Radiology. She shares insights from her extensiv...

LTR 94: The road ahead for PCCPs and AI/ML amidst chaos at the FDA 05.03.2025

This is a free preview of a paid episode. To hear more, visit naveenagarwalphd.substack.com Summary “The Digital Health Center of Excellence was hit pretty heavy, and also AI researchers at OSEL. I am not too worried about PCCP but the impact could be on how quickly FDA can finalize the other draft guidance with larger scope applied to all medical devices.” In this episode of the Let's Talk Risk P...

LTR 93: AI use cases in MedTech regulatory applications 28.02.2025

Summary “To AI or not to AI is no longer a question.” In this Let’s Talk Risk! conversation , Naveen Agarwal and Michelle Wu discuss the transformative role of AI in the regulatory space, particularly in healthcare and life sciences. They explore key trends observed at the JP Morgan Healthcare Conference, share real-world use cases of AI applications, and address concerns about trust, job security...

LTR 92: Understanding the notified body perspective on clinical evaluation 26.02.2025

Summary “When the notified body goes back and asks you (the manufacturer) for more information, they aren’t necessarily saying that whatever you have done is wrong.” Clinical evaluation is a major requirement for medical devices under the EU regulation, and notified bodies must determine whether the evidence provided by the manufacturer is scientifically valid and sufficiently complete to answer t...

LTR 91: International conference on medical device safety risk management 21.02.2025

Summary “People who were passionate about this subject (safety risk management) and were enthusiastic about it, we got together and said ‘let’s just create a conference for MedTech’, and we did.” In this Let’s Talk Risk! conversation , Naveen Agarwal interviews Bijan Elahi, a leading authority in safety risk management of medical devices. They discuss the upcoming International Safety Risk Managem...

LTR 90: Lead with empathy to grow your Quality career 14.02.2025

Summary “As a Quality leader, you need to be empathetic to other departments that are impacted by whatever change(s) you are making.” In this Let’s Talk Risk! conversation , Naveen Agarwal and Amit Tyagi explore the intersection of quality management and career growth. Amit shares insights from his extensive experience in quality engineering, emphasizing the importance of innovative thinking, risk...

LTR 89: Navigating uncertain times at the FDA 12.02.2025

This is a free preview of a paid episode. To hear more, visit naveenagarwalphd.substack.com Summary “For the foreseeable future, core FDA practices such a reviewing submissions and post-market oversight are going to continue. Smart Money says FDA in 6 months or an year from now, as to these core responsibilities, is operating similarly to FDA of mid-2024.” Yes, there is a lot of uncertainty due to...

LTR 88: Decoding Privacy Laws in Clinical Research 07.02.2025

Summary “The root cause of most privacy missteps is a lack of education, training and understanding of what the privacy rule actually is.” In this Let’s Talk Risk! conversation , Naveen Agarwal and Edye Edens delve into the critical intersection of privacy laws and clinical trials. They explore the significance of privacy regulations like HIPAA and GDPR, the implications of proposed changes to HIP...

LTR 87: A Strategic Approach to Regulatory Success with GenAI Devices 05.02.2025

This is a free preview of a paid episode. To hear more, visit naveenagarwalphd.substack.com Summary “You can definitely use (GenAI) as your core algorithm, but you need to enforce that it can only do one specific thing or at least a very clarified labeling. ” In this episode of the Let's Talk Risk Podcast , host Naveen Agarwal engages with Dr. Yujan Shrestha to explore the rapid advancements of AI...

LTR 86: Managing Post-Market Design Changes 31.01.2025

This is a free preview of a paid episode. To hear more, visit naveenagarwalphd.substack.com Summary “Mismatched design controls can feel like driving through two feet of mud. You will eventually get to your destination, but it will take a lot more time and effort than it really should. ” In this episode of the Let's Talk Risk Podcast , Naveen Agarwal and Aaron Joseph discuss the ongoing challenges...

LTR 85: The problem with CAPA problem statements 24.01.2025

“If you frame something in a certain way, you can influence the perception of its cause and the solution. ” In this Let’s Talk Risk! conversation , Jack Garvey cautions against starting a CAPA with a problem statement first. Rather, he recommends the analysis to initially begin from a factual review of both technical and situational context leading up to a CAPA, and then defining a specific proble...

LTR 84: Think of human factors for AI as levels of automation 17.01.2025

“Many of the AI/ML devices are going through De Novo and (in these) human factors considerations are specifically being called out as special controls.” In this Let’s Talk Risk! conversation , Shannon Hoste highlights some of the new concerns emerging for human factor considerations for AI/ML devices in MedTech. She explains how we could consider the level of automation as we think about new hazar...

LTR 83: Road to market for AI devices in the EU just got more complex 15.01.2025

This is a free preview of a paid episode. To hear more, visit naveenagarwalphd.substack.com Summary “Manufacturers that want to go to the European market, thinking about AI devices, it’s really important that you don’t look only at the MDR. You really have to look at the AI Act as well.” In this episode of the Let's Talk Risk Podcast , Florian Tolkmitt discusses the rapidly evolving regulatory lan...

LTR 81: 4 key themes in risk management and an upcoming conference 03.01.2025

Summary “We are all at some point, either patients or loved ones of patients. So, one way or another, we are all touched by the medical technology we create ourselves. In this episode of the Let's Talk Risk Podcast , Bijan Elahi helps us appreciate the most important aspect of our work as risk practitioners, engineers and quality/regulatory affairs professionals in the medical device industry. Tha...

LTR 80: Building safety by design into medical devices 27.12.2024

“There is a clear case to put the money into the design of the product, and control that, than relying on the human factor.” In this Let’s Talk Risk! conversation , Alex Saegert highlights the importance of focusing on risk reduction through safety by design, rather than relying on information for safety to users. He recommends risk practitioners to apply best practices from systems safety to buil...

LTR 79: Tips for SaMD development and success with FDA 20.12.2024

“Overconfidence in the performance of AI models in the development phase is a common problem.” In this Let’s Talk Risk! conversation , David Giese highlights the growing need for a rigorous, disciplined development process with the goal of meeting regulatory requirements for marketing authorization. He shares how AI developers are often over-confident in the performance of their models, but disapp...

LTR 73: It's time to up our game on medical device cybersecurity 19.12.2024

Summary “Medical devices are now increasingly connected in a hospital network. Or even if they are not, they are vulnerable to cyber attacks”. In this episode of the Let's Talk Risk Podcast, Eric Henry highlights the growing concern about security and cybersecurity of medical devices. As technology evolves and medical devices increasingly operate in an i… This is a public episode. If you'd like to...

LTR 78: New challenges in managing risks of software in IVDs 13.12.2024

“Software more than any other type of device, has integrations with other systems and devices. You have to consider a complex network of dependencies and infrastructure when analyzing risks.” In this Let’s Talk Risk! conversation , Megan Kane highlights the growing role of software, including artificial intelligence, in in-vitro diagnostic devices, including in next generation sequencing applicati...

PCCP: Opportunity for risk practitioners to shine 11.12.2024

Risk practitioners in MedTech now have a unique opportunity to help accelerate development and post-market improvement of AI/ML enabled medical devices while also reducing the regulatory burden. PCCP, or Pre-Determined Change Control Plan, is a novel regulatory approach that allows device manufacturers to include planned changes in their initial submission and avoid additional submissions in the p...

LTR 77: How GenAI is transforming Quality in MedTech 06.12.2024

This is a free preview of a paid episode. To hear more, visit naveenagarwalphd.substack.com Summary “You are not gong to lose your job to AI, but you may lose your job to someone who knows how to use AI better than you do”. In this episode of the Let's Talk Risk Podcast, we explore the benefits of applying Generative AI to improve consistency of quality system documentation in MedTech with Garth C...

EU vs. FDA: Aligned but different in their approach to safety of AI/ML devices 04.12.2024

Applications of AI in medical devices are growing rapidly. The regulatory environment in both the US and the EU is also changing fast. In this dynamic environment, it is important to stay updated and practice a flexible approach to both risk management and your regulatory strategy. Listen to a brief audio summary above , about the emerging regulatory environment in these two major jurisdictions, a...

LTR 76: Challenges and opportunities of AI/ML in MedTech 29.11.2024

“The classic thing with AI is that the hard stuff is easy and the easy stuff is hard. It can do math I cannot do, but it cannot do the reasoning I find easy.” In this Let’s Talk Risk! conversation , we discuss key challenges and opportunities for applying Artificial Intelligence/Machine Learning (AI/ML) in MedTech. This was an open conversation with a live audience as part of the weekly Let’s Talk...

LTR 70: Best practices for applying usability engineering to medical devices 28.11.2024

Summary “Apply the usability engineering process diligently, and with the spirit of inquiry. You will learn things that you never thought. And these are the things that make your device possible”. Human factors engineering, or usability engineering, is often thought of as a check-the-box activity for the purpose of regulatory compliance. But it is a lot … This is a public episode. If you'd like to...

LTR 74: AR/VR devices in MedTech 15.11.2024

In this Let’s Talk Risk! conversation , Ritam Priya advises device manufacturers to engage early with the FDA through the Q-sub program. Applications of AR/VR in MedTech are growing rapidly, but the regulatory science is still evolving. There are many specific safety and performance concerns unique to AR/VR technologies used for medical purposes. Early engagement with the FDA can help in developin...

LTR 72: A clinician's insights on risk and collaboration in MedTech 01.11.2024

“It comes down to collaboration. It comes down to intentional communication and ensuring there is trust and familiarity on both sides.” In this Let’s Talk Risk! conversation , Dr. Olaf Hedrich emphasizes the need for collaboration, building trust and familiarity between clinicians and engineers. We all have a mutual desire to do the right things for our patients, but sometimes our lens is a bit na...

Listen to the Let's Talk Risk! Podcast podcast in Replaio

Radio and podcasts in one app - free, with no sign-up. Install today and do not miss the launch

Get it on Google Play

Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.